Lactate, gut bacteria and liver cirrhosis study
Part of Digestive system clinical trials.
This study looks at how lactate-related changes in gut bacteria might affect the progression of liver cirrhosis. It includes both healthy people and cirrhosis patients to see how these factors relate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are either a healthy person with no liver disease, or a patient diagnosed with liver cirrhosis (by imaging or biopsy) and have had chronic liver disease for over 6 months.
- You are willing to take part and sign a consent form.
- You have no history of severe organ disease (like serious heart, kidney, or stomach problems), cancer, or autoimmune conditions.
- You have not had an acute infection or inflammatory illness in the past month.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is exploring a new way to predict how liver cirrhosis will progress. It may help doctors better understand and manage the condition.
This trial is looking at bacteria inside the liver of people with alcoholic hepatitis. It may help understand how these bacteria affect the disease and lead to better treatments.
This study looks at how nutrition affects the health of people with liver cirrhosis (scarred liver) and aims to build a tool to predict their outcomes. If you have cirrhosis, joining may help researchers find better ways to support your health.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
This study looks at how your body uses protein in your muscles when you have cirrhosis (a scarred liver). It uses a special “tracer” method (a substance that can be tracked) and may help researchers better understand muscle loss in people with milder cirrhosis.
This study looks at how a specific gut bacteria (Ruminococcus gnavus) and its byproducts are linked to fatty liver disease (MAFLD). It compares people with the condition to healthy individuals to better understand the connection.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.